联合CEUS LI-RADS与临床特征预测肝细胞癌GPC3表达的模型构建
回顾性分析142例肝细胞癌患者术前CEUS特征,以手术标本免疫组化为参考标准,比较GPC3阳性与阴性组临床及影像特征,构建联合临床特征与LI-RADS分类的预测模型,AUC为0.759,决策曲线显示临床获益。
要点
- 142例中GPC3阳性101例(71.1%),LI-RADS M类46例(32.4%)
- LI-RADS M类是GPC3阳性的独立危险因素(OR=2.822,95%CI 1.101-7.236,p=0.031)
- 联合模型AUC为0.759,优于单一变量(p<0.05)
核心结论
- 联合临床特征与CEUS LI-RADS的模型对预测HCC患者GPC3表达取得满意性能。
研究设计与样本
- 回顾性分析2020年1月至2021年6月本机构142例HCC患者,术前均行CEUS,以手术标本免疫组化分析为参考标准。
关键影像表现/征象
- 142例中LR-4/5病变96例(67.6%),LR-M病变46例(32.4%)。
- GPC3阳性101例(71.1%),GPC3阴性41例(28.9%)。
诊断标准与关键数值
- 多因素logistic回归显示年龄较轻(OR=0.947;95%CI 0.910-0.985;p=0.007)、甲胎蛋白>400 ng/ml(OR=5.202;95%CI 1.808-14.966;p=0.002)及LI-RADS M类(OR=2.822;95%CI 1.101-7.236;p=0.031)为GPC3阳性HCC的独立危险因素。
- 联合临床特征与LI-RADS分类的模型AUC为0.759(p<0.05),优于单一变量。
- 列线图与决策曲线显示该预测模型在预测GPC3表达方面具有实质性临床获益。
临床应用与阅片要点
- 阅片时可关注CEUS LI-RADS分类为M类的病灶,该类与GPC3阳性表达相关。
- 结合患者年龄及甲胎蛋白水平(>400 ng/ml)可辅助预测GPC3表达状态。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To establish a predictive model incorporating clinical features and contrast-enhanced ultrasound (CEUS) liver Imaging Reporting and Data System (LI-RADS) for predicting glypican-3 (GPC3) expression in hepatocellular carcinoma (HCC).
METHODS: A total of 142 HCC patients between January 2020 to June 2021 in our institution were retrospectively analyzed. All patients underwent CEUS before surgery, and the reference standard was immunohistochemical analysis of surgical specimen. The clinical features, conventional ultrasound features, and CEUS LI-RADS features of patients in the GPC3-positive and GPC3-negative groups were evaluated and compared. The variables screened by multivariable logistic regression were used to develop a model for predicting GPC3 expression and the predictive precision and clinical utility of the model was evaluated using receiver operating characteristic analysis and decision curve analysis.
RESULTS: Among the 142 HCC patients, 96 (67.6%) were classified as LR-4/5 lesions, 46 (32.4%) were classified as LR-M lesions, 101 (71.1%) were GPC3-positive and 41 (28.9%) were negative. Multivariable logistic regression analysis showed that younger age (OR = 0.947; 95% CI: 0.910-0.985; p = 0.007), alpha-fetoprotein > 400 ng/ml (OR = 5.202; 95% CI: 1.808-14.966; p = 0.002) and LI-RADS M (OR = 2.822; 95% CI: 1.101-7.236; p = 0.031) was independent risk factors for GPC3-positive HCC. The model combining clinical features and LI-RADS categories showed better performance than single variable, with AUC of 0.759 (p < 0.05). The nomogram and decision curves revealed substantial clinical benefit of the prediction model in predicting GPC3 expression.
CONCLUSION: The combined model incorporating clinical features and CEUS LI-RADS achieved a satisfactory performance for predicting GPC3 expression in HCC patients.
引用
- Huang F, Pang J, Wu Y, et al. Development of a model combining CEUS LI-RADS and clinical features for predicting glypican-3 expression in hepatocellular carcinoma. Abdom Radiol (NY). 2025. PMID: 40214698. doi:10.1007/s00261-025-04861-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。